The importance of considering competing risks in recurrence analysis of intracranial meningioma.

Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Mirian C
- Jensen LR
- Juratli TA
- Maier AD
- Torp SH
- Shih HA
- Morshed RA
- Young JS
- Magill ST
- Bertero L
- Stummer W
- Spille DC
- Brokinkel B
- Oya S
- Miyawaki S
- Saito N
- Proescholdt M
- Kuroi Y
- Gousias K
- Simon M
- Moliterno J
- Goutagny S
- Prabhu VC
- Tsiang JT
- Wach J
- Güresir E
- Yamamoto J
- Kim YZ
- Lee JH
- Koshy M
- Perumal K
- Baskaya MK
- Cannon DM
- Shrieve DC
- Suh CO
- Chang JH
- Kamenova M
- Straumann S
- Soleman J
- Eyüpoglu IY
- Catalan T
- Lui A
- Theodosopoulos PV
- McDermott MW
- Wang F
- Guo F
- Góes P
- de Paiva Neto MA
- Jamshidi A
- Komotar R
- Ivan M
- Luther E
- Souhami L
- Guiot MC
- Csonka T
- Endo T
- Barrett OC
- Jensen R
- Gupta T
- Patel AJ
- Klisch TJ
- Kim JW
- Maiuri F
- Barresi V
- Tabernero MD
- Skyrman S
- Broechner A
- Bach MJ
- Law I
- Scheie D
- Kristensen BW
- Munch TN
- Meling T
- Fugleholm K
- Blanche P
- Mathiesen T
Grupos
Abstract
BACKGROUND: The risk of recurrence is overestimated by the Kaplan-Meier method when competing events, such as death without recurrence, are present. Such overestimation can be avoided by using the Aalen-Johansen method, which is a direct extension of Kaplan-Meier that accounts for competing events. Meningiomas commonly occur in older individuals and have slow-growing properties, thereby warranting competing risk analysis. The extent to which competing events are considered in meningioma literature is unknown, and the consequences of using incorrect methodologies in meningioma recurrence risk analysis have not been investigated. METHODS: We surveyed articles indexed on PubMed since 2020 to assess the usage of competing risk analysis in recent meningioma literature. To compare recurrence risk estimates obtained through Kaplan-Meier and Aalen-Johansen methods, we applied our international database comprising~8,000 patients with a primary meningioma collected from 42 institutions. RESULTS: Of 513 articles, 169 were eligible for full-text screening. There were 6,537 eligible cases from our PERNS database. The discrepancy between the results obtained by Kaplan-Meier and Aalen-Johansen was negligible among low-grade lesions and younger individuals. The discrepancy increased substantially in the patient groups associated with higher rates of competing events (older patients with high-grade lesions). CONCLUSION: The importance of considering competing events in recurrence risk analysis is poorly recognized as only 6% of the studies we surveyed employed Aalen-Johansen analyses. Consequently, most of the previous literature has overestimated the risk of recurrence. The overestimation was negligible for studies involving low-grade lesions in younger individuals; however, overestimation might have been substantial for studies on high-grade lesions.
© 2024. The Author(s).
Datos de la publicación
- ISSN/ISSNe:
- 0167-594X, 1573-7373
- Tipo:
- Article
- Páginas:
- 503-511
- PubMed:
- 38336917
- Factor de Impacto:
- 1,022 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
JOURNAL OF NEURO-ONCOLOGY SPRINGER
Documentos
- No hay documentos
Filiaciones
Keywords
- Meningioma; Neuro-oncology; Competing risk; Recurrence
Proyectos y Estudios Clínicos
EVALUACIÓN DEL ÍNDICE DE PROLIFERACIÓN KI-67 COMO PREDICTOR DE RECIDIVA EN MENINGIOMAS CEREBRALES GRADO I DE LA OMS. COMPARACIÓN CON LA ESCALA DE RESECCIÓN QUIRÚRGICA DE SIMPSON.
Investigador Principal: LUIS RICARDO PRAT ACÍN
2013_0041_CRC_PRAT . FUNDACION MUTUA MADRILEÑA . 2013
CILENGITIDA EN PACIENTES CON GLIOBLASTOMA MULTIFORME RECIEN DIAGNOSTICADO Y CON PROMOTOR METILADO DEL GEN MGMT- ESTUDIO MULTICENTRICO, ABIERTO Y CONTROLADO EN FASE III PARA EVALUAR CILENGITIDA EN COMBINACION CON EL TRATAMIENTO CONVENCIONAL (TEMOZOLOMIDA C O N RADIOTERAPIA CONCOMIANTE, SEGUIDO POR EL TRATAMIENTO DE MANTENIMIENTO CON TEMOZOLOMIDA) FRENTE AL TRATAMIENTO CONVENCIONAL SOLO (CENTRIC)
Investigador Principal: GASPAR REYNES MUNTANER
EMD121974-011
ESTUDIO OBSERVACIONAL RETROSPECTIVO SOBRE LA EFECTIVIDAD DE GLIOLAN® EN EL TRATAMIENTO DE LOS GLIOMAS MALIGNOS EN ESPAÑA (ESTUDIO VISIONA).
Investigador Principal: CARLOS BOTELLA ASUNCION
GEB-ACA-2011-01
ESTUDIO OBSERVACIONAL PROSPECTIVO ACERCA DEL MANEJO PERIOPERATORIO / PERIPROCEDIMIENTO DE LOS FÁRMACOS ANTITROMBÓTICOS EN EL “MUNDO REAL”: REGISTRO REQXAA.
Investigador Principal: RAQUEL FERRANDIS COMES
SEC-API-2019-01 . 2021
Cita
Mirian C,Jensen LR,Juratli TA,Maier AD,Torp SH,Shih HA,Morshed RA,Young JS,Magill ST,Bertero L,Stummer W,Spille DC,Brokinkel B,Oya S,Miyawaki S,Saito N,Proescholdt M,Kuroi Y,Gousias K,Simon M,Moliterno J,PRAT R,Goutagny S,Prabhu VC,Tsiang JT,Wach J,Güresir E,Yamamoto J,Kim YZ,Lee JH,Koshy M,Perumal K,Baskaya MK,Cannon DM,Shrieve DC,Suh CO,Chang JH,Kamenova M,Straumann S,Soleman J,Eyüpoglu IY,Catalan T,Lui A,Theodosopoulos PV,McDermott MW,Wang F,Guo F,Góes P,de Paiva MA,Jamshidi A,Komotar R,Ivan M,Luther E,Souhami L,Guiot MC,Csonka T,Endo T,Barrett OC,Jensen R,Gupta T,Patel AJ,Klisch TJ,Kim JW,Maiuri F,Barresi V,Tabernero MD,Skyrman S,Broechner A,Bach MJ,Law I,Scheie D,Kristensen BW,Munch TN,Meling T,Fugleholm K,Blanche P,Mathiesen T. The importance of considering competing risks in recurrence analysis of intracranial meningioma. J Neurooncol. 2024. 166. (3):p. 503-511. IF:3,200. (2).